Abstract
OBJECTIVE: To assess the quality of evidence, identify potential biases, and verify the validity of existing studies on glioma treatment outcomes. METHODS: We extracted and analyzed data from systematic reviews and meta-analyses assessing therapies in glioma patients. Our search included PubMed, Embase, Web of Science, and the Cochrane Database up to July 2024. Two authors independently evaluated each meta-analysis for methodological quality using the AMSTAR tool, following established evidence classification guidelines. RESULTS: This study evaluated 68 meta-analyses and 389 outcomes from 4,243 articles, classifying 193 outcomes as 'very low' quality, 96 as 'low' quality, 28 (7.2%) as 'high' quality, and 72 (18.5%) as 'moderate' quality, 156 as NS, 231 (59.4%) as Class IV, and 2 (0.005%) as Class III, respectively. High-quality evidence demonstrated that combining Traditional Chinese and Western medicine, adding bevacizumab (BVZ) to chemoradiotherapy (CRT), and other specific treatments improved overall survival (OS). Molecularly targeted drugs combined with temozolomide (TMZ) and radiotherapy (RT), as well as standard therapy augmented with anti-vascular endothelial growth factor or BVZ, prolonged progression-free survival (PFS). Additionally, treatments involving RT with TMZ or TMZ alone increased adverse events, whereas high-quality evidence showed that integrated Traditional Chinese and Western medicine, compared to Western medicine alone, reduced bone marrow suppression and gastrointestinal issues, enhancing treatment efficacy. CONCLUSIONS: High-quality evidence indicates that targeted therapy, immunotherapy, CRT, integrated Chinese and Western medicine, gene therapy, and combinations of targeted therapies with CRT or chemotherapy (CT) can extend OS and PFS in gliomas. However, CT, CRT, and targeted therapies, with or without additional CT or CRT, may increase adverse events. Integrated Chinese and Western medicine alone may reduce adverse effects.